Key facts
- This page summarizes Kenneth J. Hillan's Form 4 filing for 23andMe Holding Co. (MEHCQ).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jun 2023, 16:20.
Kenneth J. Hillan - 05 Jun 2023 Form 4 Insider Report for 23andMe Holding Co. (MEHCQ)
- Reporting relationship
- Chief Therapeutics Officer
- Issuer ticker
- MEHCQ
- Reported as of
- 05 Jun 2023
- Net transaction value
- -$31,922
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2023, 16:20:51 UTC
- Prior SEC filing
- 05 Jun 2023
- Next SEC filing
- 08 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kenneth Hillan, by Kathy Hibbs, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kenneth J. Hillan filed Form 4 for 23andMe Holding Co. (MEHCQ) on 07 Jun 2023.
Change
- Previous filing in this sequence was filed on 05 Jun 2023.
- Current net transaction value: -$31,922.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ME
transaction
Class A Common Stock
Award
- Transaction value
- $0
- Shares
- +44,381
- Change %
- +23%
- Price
- $0.000000
- Shares after
- 237,223
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
ME
transaction
Class A Common Stock
Tax liability
- Transaction value
- $31,922
- Shares
- -15,347
- Change %
- -6.5%
- Price
- $2.08
- Shares after
- 221,876
- Date
- 05 Jun 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock units (the "RSUs") granted under the 23andMe Amended and Restated Annual Incentive Plan and the 23andMe Holding Co. 2021 Incentive Equity Plan (together, the "Plans") as payment of the reporting person's annual incentive bonus for the fiscal year ended March 31, 2023. The RSUs are fully vested at the time of grant and are subject to the terms and conditions of the Plans, the applicable award agreement, and applicable tax withholding obligations. Each RSU represents the contingent right to receive one share of Class A common stock of 23andMe Holding Co.
Footnote F2
The closing price on June 5, 2023, the fair market value used for the transaction date.